NEWS
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics (Nasdaq: RPTX) announced a strategic reprioritization to focus on its clinical-stage oncology programs. The company plans to reduce its workforce by 25%, primarily from the preclinical group, expecting annual savings of $15 million and extending its cash runway into H2 2026. Key highlights include:
1. Upcoming data from the MYTHIC trial(lunresertib + camonsertib) in Q4 2024
2. Potential registrational trial for lunresertib in 2025
3. Initial data from MYTHIC trial Module 4 (lunresertib + Debio 0123) in 2025
4. Initial data from TRESR trial (camonsertib monotherapy) in 2025
5. Phase 1/2 trial for RP-1664 in pediatric neuroblastoma patients
6. Phase 1 trial initiation for RP-3467 in Q4 2024
The company aims to maximize value for patients and shareholders by focusing on its most promising precision oncology programs.
1. Upcoming data from the MYTHIC trial(lunresertib + camonsertib) in Q4 2024
2. Potential registrational trial for lunresertib in 2025
3. Initial data from MYTHIC trial Module 4 (lunresertib + Debio 0123) in 2025
4. Initial data from TRESR trial (camonsertib monotherapy) in 2025
5. Phase 1/2 trial for RP-1664 in pediatric neuroblastoma patients
6. Phase 1 trial initiation for RP-3467 in Q4 2024
The company aims to maximize value for patients and shareholders by focusing on its most promising precision oncology programs.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2639Followers
107Following
28KVisitors
Follow